Calidi Biotherapeutics Faces Delisting Concerns
Ticker: CLDWW · Form: 8-K · Filed: Oct 18, 2024 · CIK: 1855485
| Field | Detail |
|---|---|
| Company | Calidi Biotherapeutics, Inc. (CLDWW) |
| Form Type | 8-K |
| Filed Date | Oct 18, 2024 |
| Risk Level | high |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $115.00 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-standards, regulatory
Related Tickers: CLDI
TL;DR
CLDI might get delisted, watch out!
AI Summary
Calidi Biotherapeutics, Inc. filed an 8-K on October 17, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company was formerly known as First Light Acquisition Group, Inc. and changed its name on April 6, 2021.
Why It Matters
This filing indicates potential issues with Calidi Biotherapeutics' continued listing on an exchange, which could impact its stock trading and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's ongoing operations and stock viability.
Key Players & Entities
- Calidi Biotherapeutics, Inc. (company) — Registrant
- First Light Acquisition Group, Inc. (company) — Former company name
- October 17, 2024 (date) — Date of earliest event reported
- April 6, 2021 (date) — Date of name change
FAQ
What specific listing rule or standard has Calidi Biotherapeutics failed to satisfy?
The filing does not specify the exact rule or standard that Calidi Biotherapeutics has failed to satisfy, only that a notice has been issued.
What is the potential consequence of failing to meet continued listing requirements?
Failure to meet continued listing requirements can lead to the delisting of the company's securities from the exchange.
When was Calidi Biotherapeutics, Inc. previously known as First Light Acquisition Group, Inc.?
Calidi Biotherapeutics, Inc. was formerly known as First Light Acquisition Group, Inc. prior to a name change on April 6, 2021.
What is the date of the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on October 17, 2024.
What is the Standard Industrial Classification (SIC) code for Calidi Biotherapeutics, Inc.?
The SIC code for Calidi Biotherapeutics, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 739 words · 3 min read · ~2 pages · Grade level 11.4 · Accepted 2024-10-18 17:25:48
Key Financial Figures
- $0.0001 — ch Registered Common stock, par value $0.0001 per share CLDI NYSE American LLC
- $115.00 — of common stock at an exercise price of $115.00 per whole share of common stock. To e
Filing Documents
- form8-k.htm (8-K) — 46KB
- ex99-1.htm (EX-99.1) — 10KB
- 0001493152-24-041623.txt ( ) — 281KB
- cldi-20241017.xsd (EX-101.SCH) — 4KB
- cldi-20241017_def.xml (EX-101.DEF) — 29KB
- cldi-20241017_lab.xml (EX-101.LAB) — 36KB
- cldi-20241017_pre.xml (EX-101.PRE) — 26KB
- form8-k_htm.xml (XML) — 6KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On October 18, 2024, the Company issued a press release announcing the receipt of the Notice. By filing this Current Report on Form 8-K and furnishing the information contained herein, the Company makes no admission as to the materiality of any information in this report that is required to be disclosed solely by reason of Regulation FD. The information in this Item 7.01 disclosure, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities under that Section. In addition, the information in this Item 7.01 disclosure, including Exhibits 99.1, shall not be incorporated by reference into the filings of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Exhibit Description 99.1 Press Release dated October 18, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CALIDI BIOTHERAPEUTICS, INC. Dated: October 18, 2024 By: /s/ Andrew Jackson Name: Andrew Jackson Title: Chief Financial Officer